Koyfin Home > Directory > Health Care > Abbvie Inc

Abbvie Inc Price Chart ABBV

Historical daily share price chart and data for Abbvie Inc since 2013 adjusted for splits and dividends. The latest closing price for Abbvie Inc as of November 23, 2020 is $102.18.
  • In 2020 the stock opened at $84.41 and closed at $102.18 for a gain of 17% YTD.
  • In 2019 the stock opened at $81.83 and closed at $83.90 for a gain of 2%.
  • In 2018 the stock opened at $83.85 and closed at $82.68 for a loss of -1%.
  • In 2017 the stock opened at $52.40 and closed at $83.48 for a gain of 37%.
View Chart On Koyfin

Abbvie Inc Summary

Stock Symbol: ABBV

Abbvie Inc Company Info

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Market Cap
Dividend Yield
5.16 %
Beta vs SPX
Short Interest
1283.84 %
30D Volatility
Hedge Fund Held
1.72 %

Last 10 Days of ABBV Prices